October 28, 2021 – Pfizer Inc. and BioNTech SE announced that the U.S. government has purchased 50 million more doses of the companies’ COVID-19 vaccine.
The U.S. will receive these additional doses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 years of age, should they receive regulatory authorization.
The companies expect to deliver all these doses by April 30, 2022.
This order is the is the final purchase option for the U.S. government under its existing supply agreement with the companies. It will bring the total number of Pfizer-BioNTech COVID-19 Vaccine doses secured under the agreement since the start of the pandemic to 600 million.
Separately, Pfizer and BioNTech have agreed to provide a total of 1 billion doses to the U.S. government at a not-for-profit price for donation to low- and lower-middle-income countries.
Pfizer and BioNTech submitted a request earlier this month to the U.S. Food and Drug Administration (FDA) for EUA of their COVID-19 vaccine in children 5 to 11 years of age. If authorized and subsequently recommended by the CDC Advisory Committee on Immunization Practices (ACIP), the companies expect to then begin shipping 10-µg pediatric doses immediately, as directed by the U.S. government. Eligible U.S. residents will continue to receive the vaccine for free.
In total, Pfizer and BioNTech expect to manufacture 3 billion doses of their COVID-19 vaccine worldwide in 2021, which includes pediatric doses. In 2022, the companies expect to manufacture 4 billion doses of the Pfizer-BioNTech COVID-19 Vaccine worldwide, which also includes pediatric doses.